NESSCA Validation and Responsiveness of Several Rating Scales in Spinocerebellar Ataxia Type 2

NESSCA Validation and Responsiveness of Several Rating Scales in Spinocerebellar Ataxia Type 2

Author Monte, Thais L. Google Scholar
Reckziegel, Estela R. Google Scholar
Augustin, Marina C. Google Scholar
Silva, Amanda S. P. Google Scholar
Locks-Coelho, Lucas D. Google Scholar
Barsottini, Orlando Autor UNIFESP Google Scholar
Pedroso, Jose L. Autor UNIFESP Google Scholar
Vargas, Fernando R. Google Scholar
Saraiva-Pereira, Maria-Luiza Google Scholar
Leotti, Vanessa Bielefeldt Google Scholar
Jardim, Laura Bannach Google Scholar
Abstract Spinocerebellar ataxia type 2 (SCA2), caused by a CAG expansion (CAGexp) at ATXN2, has a complex clinical picture. While validated ataxia scales are available, comprehensive instruments to measure all SCA2 neurological manifestations are required. This study aims to validate the Neurological Examination Score for the assessment of Spinocerebellar Ataxias (NESSCA) to be used in SCA2 and to compare its responsiveness to those obtained with other instruments. NESSCA, SARA, SCAFI, and CCFS scales were applied in symptomatic SCA2 patients. Correlations were done with age at onset, disease duration, CAGexp, and between scales. Responsiveness was estimated by comparing deltas of stable to worse patients after 12 months, according to Patient Global Impression of change, and the area under the curve (AUC) of the Receiver Operating Characteristics curve of scores range. Eighty-eight evaluations (49 patients) were obtained. NESSCA had an even distribution and correlated with disease duration (r = 0.55), SARA (r = 0.63), and CAGexp (rho = 0.32): both explained 44% of NESSCA variance. Deltas (95% CI) after 1 year in stable and worse patients were only significantly different for SARA. NESSCA, SARA, SCAFI, and CCFS AUC were 0.63, 0.81, 0.49, and 0.48, respectively. NESSCA is valid to be used in SCA2. However, the only instrument that presented good responsiveness to change in 1 year was SARA. We suggest that NESSCA can be used as a secondary outcome in future trials in SCA2 due to the burden of neurological disabilities related to disease progression.
Keywords Neurological Examination Score for Spinocerebellar Ataxia
Spinocerebellar ataxia type 2
Language English
Sponsor CNPq-Conselho Nacional de Desenvolvimento Científico e Tecnológico
FIPE-HCPA-Fundo de Incentivo a Pesquisa do Hospital de Clinicas de Porto Alegre
INAGEMP-Instituto Nacional de Genetica Medica Populacional
Grant number CNPq: 78057/2012-1
Date 2017
Published in Cerebellum. New York, v. 16, n. 4, p. 852-858, 2017.
ISSN 1473-4222 (Sherpa/Romeo, impact factor)
Publisher Springer
Extent 852-858
Access rights Closed access
Type Article
Web of Science ID WOS:000405033000012

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account